60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 28, 2022 16:48 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
January 24, 2022 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event
January 05, 2022 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 19, 2021 16:05 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 10, 2021 16:05 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 23, 2021 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 16, 2021 16:05 ET | Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR
September 08, 2021 08:00 ET | Soleno Therapeutics
Statistically significant reduction in hyperphagia and all other PWS behavioral parameters in Study C602 Statistically significant improvements compared to natural history of PWS from the PATH...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
July 28, 2021 16:05 ET | Soleno Therapeutics
REDWOOD CITY, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
60d80446-7430-42e7-a2ff-c1e637154612.png
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
July 06, 2021 08:00 ET | Soleno Therapeutics
REDWOOD CITY, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...